Neither approach is wrong, but you should be consistent
If you have any doubts, you can contact us anytime
Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
So, if you crave something sweet, what should you reach for instead
When comparing patients who initiated treatment with exenatide (n=14,076, median follow-up: 969 days), to those starting dulaglutide (n=54,787, median follow-up: 948 days) or liraglutide (n=25,562, median follow-up: 1,007 days), no differences were found in the hazard of composite treatment for diabetic macular edema (DME) and/or proliferative DR: exenatide vs